According to Fact.MR, a leading provider of market research and competitive intelligence, the global GMP Cell Banking Service Market is anticipated to reach approximately US$ 882.1 million by 2024. Over the period from 2024 to 2034, the market for GMP cell banking services is expected to witness a robust growth rate of 13.7%. The report further forecasts that the market will attain an overall valuation of US$ 3,123.5 million by the conclusion of this forecast period.
GMP cell banking services play a crucial role in ensuring the quality, purity, and traceability of cell lines utilized in the research and development of new treatments. Moreover, these services mitigate the risk of contamination and fluctuations in drug prices by ensuring consistency and quality in cell lines.
For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9248
Top Key Players
WuXi AppTec, Charles River Laboratories, Eurofins Scientific, Merck KGaA, Lonza, SGS Life Sciences Ltd., ViruSure, Austrianova, Goodwin Biotechnology, Paragon Bioservices, Bio Reliance, Sartorius, Thermo Fisher, BSL Bioservice, Cleancells, Covance
Market Segmentations
By Cell Type: Mammalian, Microbial, Insect, Yeast, Avian, Stem, Others
By End User: Biopharmaceutical Companies, Contract Manufacturing Organizations
By Region: North America, Europe, Latin America, East Asia, South Asia & Oceania, The Middle East & Africa
The size and competitiveness of different GMP cell line end users are anticipated to determine the future growth prospects for the market under discussion. Companies that can deploy modern equipment to produce and preserve cell lines are expected to adapt to the ever-changing GMP cell banking services market.
Key Takeaways from the Global GMP Cell Banking Service Market Study Report
- The United States is the leading market for GMP cell banking services, which is expected to advance with a 13.1% annual growth rate till 2034.
- Canada is estimated to have around 22.8% of the North American market and is projected to follow 12.7% CAGR through 2034.
- In Europe, Germany is observed to have around 33.4% of the total demand for GMP cell banking services. The regional market is projected to expand further at 12% per year between 2024 and 2034.
- The adoption of GMP cell banking services in the United Kingdom spurred after the pandemic, and it is likely to experience a 10.7% CAGR through 2034.
Competitive Landscape
A few leading players hold a significant share of the global market and offer complete GMP-compliant services, encompassing characterization, testing, and storage. Businesses that outsource cell banking services also look for partners who have experience, resources, and a history of adhering to GMP regulations.
Recent Developments
- In September 2022, FUJIFILM Diosynth Biotechnologies revealed that it was expanding its large-scale microbial production facility at the Billingham campus located in the United Kingdom.
- In April 2022, SGS collaborated with Liveome, a drug developer based in Korea, to formulate, develop, and clinically manufacture a targeted-release formulation containing lyophilized microbial cells.
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=9248
Biopharmaceutical Companies Increasingly Rely on Outsourcing to CMOs
According to market analysis, there is a projected 13.9% Compound Annual Growth Rate (CAGR) in the demand for GMP cell banking services by contract manufacturing companies through 2034.
The current trend in the biopharmaceutical industry involves outsourcing specific phases of the production process to contract manufacturing organizations (CMOs). Biopharmaceutical companies find that collaborating with CMOs not only provides access to infrastructure and expertise at a reasonable cost but also proves to be a more efficient alternative to developing internal cell line banking capabilities, which can be resource-intensive.
At the Core: Efficiency and Quality Assurance Requirements of Biopharmaceutical Companies
A survey across various end-use verticals for GMP cell banking service providers reveals that biopharmaceutical companies contribute to over 70% of the total demand. The analysis suggests a CAGR of 13.3% for this segment between 2024 and 2034.
GMP cell banking services play a crucial role for biopharmaceutical companies in ensuring the consistency, quality, and legal compliance of the cell lines used in developing new drugs. Additionally, these services streamline the time required for the development and commercialization of treatments by providing ready-to-use and compliant cell banks.